Key facts
- It has raised $150K; the latest was Seed Round in Jan 2026.
- Notable investors include SOSV, IndieBio, University of California, MassBio, Merck Digital Sciences Studio — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Augment Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for Augment Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Augment Biologics
Operator of a biotechnology research company intended to develop a glycoprotein drug. The company offers AI-guided glyco templating for glycobiology, transforming biologic drug development, enabling the biopharmaceutical industry to enhance drug efficacy, safety, durability and manufacturing efficiency.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2021
- Website
- augmentbiologics.com/
- Ownership
- Privately Held (backing)
Augment Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Augment Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Augment Biologics in its N-PORT filings yet. We sweep new filings monthly.